Topical Application of a Dual ABC Transporter Substrate and NF-κB Inhibitor Blocks Multiple Sources of Cutaneous Inflammation in Mouse Skin

Among the molecular signals underlying cutaneous inflammation is the transcription complex NF-kappa B, its upstream modulators, and cytokines and chemokines that are the downstream proinflammatory effectors. Central to NF-kappa B activation is I kappa B kinase (IKK), which phosphorylates I kappa B alpha, releasing NF-kappa B to the nucleus. In a screening of a kinase inhibitor library, we identified two IKK inhibitors that were high-affinity substrates for p-glycoprotein (ABCB1), the multidrug resistance protein known to facilitate transdermal drug delivery. ACHP (2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-4-(4-piperidinyl)-3-pyridinecarbonitrile) and IKK 16 prevented both nuclear translocation of NF-kappa B and activation of a NF-kappa B reporter and reduced the induction of cytokine and chemokine transcripts in human or mouse keratinocytes by IL-1 alpha, tumor necrosis factor-alpha, and phorbol myristate acetate. ACHP, but not IKK 16, was nontoxic to mouse or human keratinocytes at any dose tested. In mice, topical ACHP prevented the cutaneous inflammation induced by topical phorbol myristate acetate or imiquimod, reduced the inflammation from erythema doses of artificial sunlight, and lowered the tumor incidence of mice treated with 7,12-dimethyl benzanthracene when applied before phorbol myristate acetate. Topical ACHP also reduced the NF-kappa B and IL-17 inflammatory signature after multiple doses of imiquimod. Thus, ACHP and IKK 16 hit their NF-kappa B target in mouse and human keratinocytes, and ACHP is an effective topical nonsteroidal anti-inflammatory in mice.